Enliven Therapeutics, Inc. · NASDAQ:ELVN

Orbimed Advisors LLC reported a 10.93% stake in Enliven Therapeutics, Inc. (Schedule 13D/A)

Event Jun 15, 2026 · Filed Jun 17, 2026

Orbimed Advisors LLC reported a 10.93% stake in Enliven Therapeutics, Inc., 7,634,630 shares, with active intent on Jun 15, 2026. Filed Jun 17, 2026 (Schedule 13D/A).

Stake
10.93%
Shares
7,634,630
Intent
Active
What changed
Stake changed
Filed together
4 holders

The filing in full

HolderStakeShares
ORBIMED ADVISORS LLC10.93%7,634,630
ORBIMED CAPITAL GP VII LLC10.58%7,388,902
ORBIMED GENESIS GP LLC0.35%245,728
ORBIMED CAPITAL LLC0.04%31,132

Source

View original at SEC

Related